Comparative Study of Low-dose Pioglitazone or Metformin Treatment in Ia pa nese Diabetic Patients with Metabolic Syndrome

Experimental and Clinical Endocrinology and Diabetes

Volumn 117, Issue 10, 2009, Pages 593-599

  Kato, T ^a   Sawai, Y ^a   Kanayama, H ^a   Taguchi, H ^a   Terabavashi, T ^a   Taki, F ^a   Yamada, K ^a   Yamazaki, Y ^a   Hayakawa, N ^b   Suzuki, A ^b   Oda, N ^b   Katada, N ^a   Itoh, M ^b,c  

^a Aichi Prefectural Welfare Federation of Agricultural Cooperatives   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Department of Internal Medicine   (Japan)

Author keywords

Atherosclerosis; Metabolic syndrome; Metformin; Pioglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTERIOSCLEROSIS; ARTICLE; BODY MASS; CARDIOVASCULAR SYMPTOM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOGRAPHY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; JAPAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; PATIENT SELECTION; RADIOIMMUNOASSAY; THIAZOLIDINEDIONES; TREATMENT OUTCOME; ULTRASONOGRAPHY; WAIST CIRCUMFERENCE;

EID: 70450265353     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1202792     Document Type: Article

References (51)

1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-1062 (Pubitemid 41338752)
2. AranoffS,RosenblattS,BraithwalteSetal. Pioglitazonehydrochloridemonotherapy improvesglycemiccontrolinthetreatmentofpatientswithtype2diabetes: A6-monthrandomizedplacebo-controlleddose-responsestudy: ThePioglitazone001StudyGrouDiabetesCare2000;23:1605-1611(Pubitemid30812632)
3. Bailey CJ, Flatt PR, Ewan C. Anorectic effect of metformin in lean and genetically obese hyperglycemic (ob/ob) mice. Arch Int Pharmacodyn Ther 1986; 282: 233-239
4. Bakris GL, Viberti G, Weston WM et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes mellitus. J Hum Hypertens 2003; 17: 7-12 (Pubitemid 36163426)
5. Bioomgarden ZT. Definitions of the insulin resistance syndrome : the 1 st World Congress on the Insulin Resistance Syndrome. Diabetes Care 2004; 27: 824-830
6. Buchanan TA, Meehan WP, Jeng YY et al. Blood pressure lowering by pioglitazone Evidence for adirect vascular effect. J Clin Invest 1995; 96: 354-360
7. Bugianesi E, Bugiamsi E, Centilcore E et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100: 1082-1090 (Pubitemid 40769045)
8. CaterinaR,MarchettiP,BerniniWetal. Thedirecteffectsofmetforminonplateletfunctioninvitro.EurJClinPharmacol1989;37: 211-213(Pubitemid19215467)
9. ChanJCN,TomlinsonB,CritchleyJAJHetal. Metabolicandhemodynamiceffectsofmetoforminand glibenclamideinnormotensiveNIDDMpatients.DiabetesCare1993;16: 1035-1038(Pubitemid23184537)
10. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657
11. DeFronzo RA, Ferannini E. Insulin resistance-A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173
12. DeFronzo RA, Goodman AM. The multicenter metformin study group Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-549
13. Dormandy JA, Charbonnel B, Eckland DJ étal. PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macrovascular Events); a randomized controlled trial. Lancet 2005; 366:1279-1289
14. Examination Committee for Metabolic SyndromeDiagnostic Criteria: Japanese Metabolic Syndrome Diagnostic Criteria. J Jpn Soc Intern Med 2005; 94: 794-809
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesteivl in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
16. Garber AJ, Duncan TG, Goodman AM et al. Efficacy of metformin type II diabetes-results of a double-blind. Placebo-controlled, doseresponse trial. Am J Med 1997; 102: 491-497 (Pubitemid 28018651)
17. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factor : observations from aclinical practice. Endocr Pract2001; 7: 162-169
18. Glueck CJ, Fontaine RN, Wang P et al. Metformin reduces weight, central obesity, insulin, leptin and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001 ; 50: 856-861 (Pubitemid 32700469)
19. Haffner SM, Kennedy E, Gonzalez C et al. A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138-1141
20. Guideline Subcommittee. Japanese society of hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl): S1-S105
21. Hanefeld M, Brunetti P, Schernthaner GH et al. Quartet Study Group, One-year glycémie control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-147
22. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872 (Pubitemid 28135963)
23. InzucchiSE.Oralantihyperglycemictherapyfortype2diabetes:scientificreview. JAMA2002;287:360-372(Pubitemid34256388)
24. Kaplan NM. The deadly qualtet-Upper body obesity, glucose intolerance, hyperglyceridemia, and hypertension-. Arch Intern Med 1989; 149:1514
25. Khan M, XU Y, Edwards G et al. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies. Mariz Int J Clin Prat 2004; 58: 907-912 (Pubitemid 39642610)
26. Marchesini G, Brizi M, Blanchi G et al. Metformin in non-alcoholic steatohepatitis. Lancet 2002; 358: 893-894
27. Matsuzawa Y, Funahashi T, Nakamura T. Molecular Mechanism of Metabolic Syndrome X : Contribution of Adipocytokines Adipocytederived Bioctive Substances. Ann NY Acad Sei 1999; 892:146
28. Misbin RI. Phenformin-associated lactic acidosis : pathogenesis and treatment. Ann Intern Med 1977; 87: 591
29. Mitchell BD, Kammerer CM, Mahaney MC et al. Genetic analysis of the 1RS : Pleiotropic effects of genes influencing insulin levels on lipoprotein and obesity measures. Arterioscler Thromb Vase Biol 1996; 16: 281-288
30. Morikang E, Benson SC, Kurtz TW et al. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myoeytes. Am J Hypertens. 1997; 10: 440-446 (Pubitemid 27195980)
31. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-629
32. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972 (Pubitemid 44156663)
33. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure : a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948 (Pubitemid 37517824)
34. Nolan JJ, Ludvik KB, Beerdsen P et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331: 1188-1193 (Pubitemid 24331336)
35. Otsuka A. Effective remedy against edema and increased weight caused by pioglitazone - examination on 2 cases with type ii diabetes who have responded to pioglitazone. Prog Med 2004; 24: 1809-1812
36. Paolisso G, Amato L, Eccellente R et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28: 441-446 (Pubitemid 28326408)
37. Poirier P, Lemieux I, Mawiège P et al. Impact of waist circumference on the relationship between blood pressure and insulin : the Quebec Health Survey. Hypertension 2005; 45: 363-367 (Pubitemid 40315804)
38. Promrat K, Lutchman G, Uwaifb GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatolpgy 2004; 39: 188-196 (Pubitemid 38461481)
39. Rasfein P, Rappaport EB, Cole ST, Yan Y et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278-284
40. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595
41. Shimizu H, Uehara Y, Masunaga M et al. Affects on weight fluctuations caused by metformin hydrochloride treatment in patients with type II diabetes. Prog Med 2002; 22: 450-453
42. 2+currents and not endothelial nitric oxide production. Diabetes 1997; 46: 659-664
43. Tack CL, Ong MK, Lutterman JA et al. Insulin-induced vasodilation and endothelial function in obesity/insulin resistance: effects of troglitazone. Diabetologia 1998; 41: 569-576
44. UK Prospective Diiabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet 1998; 352: 854-865
45. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva; 1999
46. Wulffele MG, Kooy A, Zeeuw D de et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type2 diabetes mellitus : a systematic review. J Intern Med 2004; 256: 1-14 (Pubitemid 38813614)
47. Yamauchi T, Kamon J, Waki H et al. The mechanisms by which both heterozygous PPARa deficiency and PPARa agonist improve insulin resistance. J Biol Chem 2001a; 276: 41245-41254
48. Yamauchi T, Kamon J, Waki H et al.The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001b; 7: 941-946 (Pubitemid 32756432)
49. Zanchi A, Chiolero A, Maillard M et al. Effects of the peroxisomal proliferators-activated receptor-gamma agonist pioglitazoneon renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004; 89: 1140-1145 (Pubitemid 38368402)
50. Zhang HY, Ready SR, Kotchen TA. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 1994; 24: 106-110
51. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2004; 108: 1167-1174